#Canada #Montreal #biotechnology #funding #DropGenie

DropGenie Secures $5 Million Seed+ Financing to Scale Functional Biology Development

In a significant move for the biotechnology sector, DropGenie has announced it has raised $5 million in Seed+ financing to enhance its functional biology platform. This funding will aid in the expansion of partnerships aimed at providing critical decision-ready discovery data derived from patient cells.

Founded in Montreal, DropGenie specializes in creating valuable biological data that is key for drug development. The recent investment was led by BDC Thrive Venture Fund, accompanied by insights from notable partners including Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Quebec.

Innovative Solutions for Drug Development

DropGenie's innovative approach allows researchers to utilize primary human cells in high-efficiency workflows, drastically reducing the amount of cells and reagents needed for experiments. This advancement in technology presents an opportunity for pharmaceutical companies and biotech firms to conduct scalable studies that were previously hindered by resource limitations.

Alison Hirukawa, Co-founder and CEO of DropGenie, expressed excitement about the funding, stating, "Primary human cells hold the answers drug developers need, but they've been too scarce to study at scale. We make those experiments practical, and BDC Thrive Fund helps us bring that to more teams, faster."

This funding round is expected to propel the commercialization of DropGenie's flagship product in the upcoming months, providing more researchers access to groundbreaking capabilities that facilitate gene editing workflows.

Expanding Opportunities and Accessibility

As part of its growth strategy, DropGenie is not only looking to integrate its products within major pharmaceutical and biotech companies but also to evolve its business model. This includes offering various methods for clients to engage with the company—whether running protocols in-house, utilizing DropGenie's expertise through service contracts, or forming vital data partnerships.

BDC's Thrive Venture Fund is specifically designed to support women-led tech firms in Canada from their inception through Series B funding rounds. This investment in DropGenie represents a long-term partnership that the company can rely on as it aims for global expansion.

Mona Minhas, Managing Partner of the BDC Thrive Venture Fund, stated, "DropGenie is building critical infrastructure for the future of drug discovery by making high-quality, human-relevant biological data more accessible and scalable. We see an opportunity to build a globally important company from Canada, and Alison has the scientific depth, ambition, and vision to lead it. We're proud to back her and the DropGenie team as they scale globally."

Future Prospects

With planned rollouts in early 2027, DropGenie is building collaborations with leaders in the primary-cell applications sector to provide robust services. Their goal is to enable teams to generate functional data efficiently through their platform, thereby enhancing the research landscape significantly.

For those interested in learning more about how DropGenie can benefit their research, additional details can be found on their official website, www.dropgenie.com.

The company’s dedication to innovation and its foresight in integrating technology with drug development processes mark it as a key player in the evolving biotechnology field.

About DropGenie

Based in Montreal and Boston, DropGenie is at the forefront of revolutionizing how primary patient cells can be utilized in large-scale experiments. Their automated microfluidic platform allows for precision and efficiency, ultimately contributing to advancements in cell therapy and functional genomics. The continuity of quality assurance in drug development is paramount, and DropGenie's approach offers a timely solution.

As a company committed to changing the landscape of functional biology, DropGenie stands to significantly impact the future of AI-driven drug discovery, firmly establishing its vision in the annals of biotechnology advancement.